{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:10Z","timestamp":1786119430419,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis that can lead to progressive joint damage and impaired quality of life. Although biologic therapies targeting key inflammatory pathways have advanced rapidly, global research trends and hotspots in PsA treatment have not been systematically characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Publications on PsA treatment from 2014 to 2024 were retrieved from the Web of Science Core Collection. Bibliometric and visualization analyses were performed using CiteSpace and VOSviewer to evaluate publication characteristics, collaborative networks, and research trends, including keyword co-occurrence and citation burst analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 2704 publications were included. The United States ranked first in both publication output and citations, with extensive international collaboration, particularly with European countries, while contributions from the Asia-Pacific region have increased in recent years. Research focus has shifted over time from tumor necrosis factor inhibitors and clinical validation studies to interleukin-17\/23 inhibitors, Janus kinase inhibitors, and personalized treatment strategies. Annals of the Rheumatic Diseases was the most influential journal, and Mease PJ was the most productive author. Keyword and citation analyses indicated that precision medicine, novel therapeutic targets, and combination therapies are emerging research directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Research on PsA treatment has evolved toward precision and targeted therapy. Future studies should emphasize biomarker-guided treatment and optimization of combination strategies to improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048472","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:04:24Z","timestamp":1777273464000},"page":"e48472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Research trends and priorities in the treatment of psoriatic arthritis from 2014 to 2024: A bibliometric and visualization study"],"prefix":"10.1097","volume":"105","author":[{"given":"Liwen","family":"Zhang","sequence":"first","affiliation":[{"name":"The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diqian","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-4801","authenticated-orcid":false,"given":"Wenzhe","family":"Bai","sequence":"additional","affiliation":[{"name":"The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, China"},{"name":"Department of Orthopedics, Affiliated Hospital of Shandong Traditional Chinese Medicine University, Jinan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","article-title":"Classification and diagnostic criteria for psoriatic arthritis.","volume":"64","author":"Helliwell","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12016-012-8302-6","article-title":"Psoriatic arthritis: a critical review.","volume":"44","author":"Dhir","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis.","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R4-20260622","first-page":"49","article-title":"Clinical presentation of psoriatic arthritis.","volume":"59","author":"Scarpa","year":"2007","journal-title":"Reumatismo"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","article-title":"Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.","volume":"71","author":"Strand","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs.","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R7-20260622","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11655-020-3429-4","article-title":"A bibliometric analysis and visualization of current research trends in Chinese medicine for osteosarcoma.","volume":"28","author":"Yin","year":"2022","journal-title":"Chin J Integr Med"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature.","volume":"57","author":"Chen","year":"2005","journal-title":"J Am Soc Inf Sci"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"e29794","DOI":"10.1016\/j.heliyon.2024.e29794","article-title":"Development and trends in metabolomics studies in psoriasis: a bibliometric analysis of related research from 2011 to 2024.","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"e35446","DOI":"10.1016\/j.heliyon.2024.e35446","article-title":"Research trends and hotspots in biologics for plaque psoriasis: a bibliometric study from 2004 to 2023.","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"key":"R13-20260622","first-page":"145","article-title":"Bibliometric analysis of the top 100 cited articles in psoriatic arthritis.","volume":"5","author":"Berlinberg","year":"2020","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"R14-20260622","first-page":"819312","article-title":"Global trends and hotspots in psoriasis research: a bibliometric analysis.","volume":"9","author":"Yu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"1507340","DOI":"10.3389\/fmicb.2024.1507340","article-title":"Research trends and focus of prosthetic joint infections from 2013 to 2023: bibliometric and visualization studies.","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Microbiol"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.joi.2018.03.005","article-title":"Examining the usage, citation, and diffusion patterns of bibliometric mapping software: a comparative study of three tools.","volume":"12","author":"Pan","year":"2018","journal-title":"J Informetrics"},{"key":"R17-20260622","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases.","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"R18-20260622","article-title":"Discusses head-to-head BE BOLD clinical trial.","author":"Mease","year":"2024","journal-title":"Dermatology Times"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","article-title":"Phase 2 trial of deucravacitinib in psoriatic arthritis: biomarkers associated with disease activity, pharmacodynamics, and clinical responses.","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis.","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"R21-20260622","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R22-20260622","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"R23-20260622","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"R24-20260622","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keae172","article-title":"Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel.","volume":"64","author":"Coates","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20260622","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"R26-20260622","doi-asserted-by":"crossref","first-page":"e15759","DOI":"10.1111\/dth.15759","article-title":"Latest combination therapies in psoriasis: narrative review of the literature.","volume":"35","author":"Diotallevi","year":"2022","journal-title":"Dermatol Ther"},{"key":"R27-20260622","doi-asserted-by":"crossref","first-page":"108318","DOI":"10.1016\/j.clim.2019.108318","article-title":"Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: a review of literature.","volume":"211","author":"Pouw","year":"2020","journal-title":"Clin Immunol"},{"key":"R28-20260622","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3390\/ijms25115793","article-title":"The Association between genetics and response to treatment with biologics in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases: a systematic review and meta-analysis.","volume":"25","author":"Al-Sofi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R29-20260622","first-page":"231","article-title":"Towards personalized medicine in psoriasis: current progress.","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"R30-20260622","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrrheum.2011.169","article-title":"Genetics of susceptibility and treatment response in psoriatic arthritis.","volume":"7","author":"O\u2019Rielly","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R31-20260622","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2014.1111","article-title":"Combined use of systemic agents for psoriasis: a systematic review.","volume":"150","author":"Busard","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R32-20260622","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","article-title":"Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics.","volume":"223","author":"Feldmann","year":"2008","journal-title":"Immunol Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:29Z","timestamp":1786039709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048472","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}